Vaccines

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

A landmark trial for Roche’s Gazyva shows unprecedented success in treating primary membranous nephropathy, offering hope of preventing kidney failure.

A new online pharmacy is challenging the 'prescribe and forget' model for weight loss drugs, offering integrated clinical care to combat safety concerns.

The firm reports a $195M cash reserve but a wider net loss as it nears crucial data readouts for its novel depression and anxiety drug candidates.

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

With a year of strong growth, key partnerships, and pipeline progress, all eyes are on ALK's upcoming annual results for 2025.

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

With a new chair from Genmab and a board of industry titans, BioNJ is poised to bolster New Jersey's status as a global biotech powerhouse.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

Often dismissed as a simple stomach bug, norovirus is a serious threat. Health experts reveal why hand sanitizer fails and what you must do to stay safe.

With promising new data for its cancer and obesity pipeline, Corbus Pharmaceuticals prepares for a crucial investor presentation at the Oppenheimer conference.

The vaccine maker posts record 2025 earnings on mpox demand but signals a strategic shift, prioritizing its travel vaccine portfolio over new R&D.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

As Caroline Dorsa retires, Biogen elects Dr. Maria Freire as its new chair, a strategic move placing deep scientific expertise at the helm for a critical period.

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

At a key summit, Candel Therapeutics will showcase how its oncolytic virus, CAN-3110, uses biomarkers to fight one of the deadliest brain cancers.

With major conferences ahead, clinical-stage MBX Biosciences aims to impress investors with its promising peptide therapies for endocrine and metabolic disorders.